South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral
Takeda has unexpectedly withdrawn its marketing application with the FDA for dengue fever vaccine TAK-003 and said it will reconsider whether it will attempt to bring it t
The US regulator has started a priority, six-month review of Takeda's dengue fever vaccine TAK-003 – tipped as a potential blockbuster product – making a decision likely in the first half o
Japan's Takeda has secured its first regulatory approval – in Indonesia – for its dengue fever vaccine TAK-003, which has been tipped as a potential blockbuster product.
Takeda has reported positive new, long-term results in its pivotal trial of dengue fever vaccine TAK-003 that builds the case for the shot as regulators review marketing applications.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
